SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Cormorant Asset Management, LP</u>		2. Date of Event Requiring Statement (Month/Day/Year) 10/30/2018		3. Issuer Name and Ticker or Trading Symbol <u>Axonics Modulation Technologies, Inc.</u> [ AXNX ]				
(Last) (First) (Middle) 200 CLARENDON STREET, 52ND FLOOR				4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner		er (Mo	5. If Amendment, Date of Original Filed (Month/Day/Year)	
(Street) BOSTON MA	02116			Officer (give title below)	Other (spe below)		licable Line) Form filed b	t/Group Filing (Check y One Reporting Person y More than One erson
(City) (State)	(Zip)	Table I. No.	n Dariyati	vo Coourition Donoficial	he Owned			
Table I - I         1. Title of Security (Instr. 4)		Table I - No	2	Amount of Securities eneficially Owned (Instr. 4)	3. Ownersh Form: Direc or Indirect ( (Instr. 5)	ct (D)   (Instr		Beneficial Ownership
	(e			e Securities Beneficially nts, options, convertible		s)		
1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Date	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	ce of Direct (D) rivative or Indirect	
Series B-2 Convertible P	referred Stock	(1)	(1)	Common Stock	500,000	(1)	<b>D</b> <sup>(2)(4)</sup>	
Series C Convertible Pre	ferred Stock	(1)	(1)	Common Stock	460,413	(1)	D <sup>(3)(4)</sup>	
(Last)       (First)       (Middle)         200 CLARENDON STREET, 52ND FLOOR         (Street)         BOSTON       MA       02116         (City)       (State)       (Zip)         1. Name and Address of Reporting Person*         Cormorant Global Healthcare Master Fund, LP			-					
(Last)     (First)     (Middle)       200 CLARENDON STREET, 52ND FLOOR			~					
(Street) BOSTON MA	02116	i						
(City) (Sta	te) (Zip)		_					
1. Name and Address of Reporting Person <sup>*</sup> <u>CORMORANT PRIVATE HEALTHCARE</u> <u>FUND I, LP</u>								
(Last) (First) (Middle) 200 CLARENDON STREET, 52ND FLOOR								
(Street) BOSTON MA	02116							

(City)	(State)	(Zip)					
1. Name and Address of Reporting Person <sup>*</sup> Chen Bihua							
	(First) Γ ASSET MANAGE STREET, 52ND FL						
(Street) BOSTON (City)	MA (State)	02116 (Zip)					

## Explanation of Responses:

1. The convertible preferred stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering.

2. Series B-2 Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 105,313 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), (ii) 375,000 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), and (iii) 19,687 shares held by a managed account (the "Account").

3. Series C Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 80,821 shares held by the Master Fund, (ii) 363,157 shares held by Fund I, and (iii) 16,435 shares held by the Account

4. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

<u>/s/ CORMORANT ASSET</u> <u>MANAGEMENT, LP, By:</u> <u>Comorant Asset Management</u> <u>GP, LLC, its General Partner,</u> <u>By: Bihua Chen, Managing</u> <u>Member</u>	<u>10/30/2018</u>
<u>/s/ CORMORANT GLOBAL</u> <u>HEALTHCARE MASTER</u> <u>FUND, LP, By: Cormorant</u> <u>Global Healthcare GP, LLC, its</u> <u>General Partner By: Bihua</u> <u>Chen, Managing Member</u>	10/30/2018
<u>/s/ CORMORANT PRIVATE</u> <u>HEALTHCARE FUND I, LP</u> <u>By: Cormorant Private</u> <u>Healthcare GP, LLC, its</u> <u>General Partner By: Bihua</u> <u>Chen, Managing Member</u>	<u>10/30/2018</u>
<u>/s/ Bihua Chen</u>	<u>10/30/2018</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.